A first aspect of the invention relates to novel compounds and more precisely to novel bifunctional prodrugs and drugs. An additional aspect of the invention relates to antibody compound conjugates, wherein the compound is a claimed compound, and to pharmaceutical compositions containing the compound or antibody compound conjugate. The invention lastly relates to the use of this compound or antibody compound conjugates according to the invention in order to treat tumour diseases, particularly in mammals.

A first aspect of the invention relates to novel compounds and more precisely to novel bifunctional prodrugs and drugs. An additional aspect of the invention relates to antibody compound conjugates, wherein the compound is a claimed compound, and to pharmaceutical compositions containing the compound or antibody compound conjugate. The invention lastly relates to the use of this compound or antibody compound conjugates according to the invention in order to treat tumour diseases, particularly in mammals.

The present disclosure relates to 2-alkynylmannose Derivative and Application Thereof. The mannose derivatives, and a pharmaceutically acceptable salt, an isotope, and an isomer thereof have a structure shown as formula I:

##STR00001##

and are used for treating or preventing bacterial infections. The present disclosure also provides pharmaceutically acceptable compositions comprising the above compounds and their use in the treatment or prevention of bacterial infections.

The present disclosure relates to 2-alkynylmannose Derivative and Application Thereof. The mannose derivatives, and a pharmaceutically acceptable salt, an isotope, and an isomer thereof have a structure shown as formula I:

##STR00001##

and are used for treating or preventing bacterial infections. The present disclosure also provides pharmaceutically acceptable compositions comprising the above compounds and their use in the treatment or prevention of bacterial infections.

Polymorphic forms of deoxycytidine and methods for preparing the same are provided herein. Also provided are compositions comprising polymorphic forms of deoxycytidine and at least one residual solvent, as well as methods of treating mitochondrial diseases using said compositions.

Polymorphic forms of deoxycytidine and methods for preparing the same are provided herein. Also provided are compositions comprising polymorphic forms of deoxycytidine and at least one residual solvent, as well as methods of treating mitochondrial diseases using said compositions.

There is provided with a porphyrin compound represented by Formula (I) or a salt thereof; ##STR00001## where A is a linking group represented as —X—NHCO— where X is a C.sub.1 to C.sub.6 alkylene group, each of R.sub.1, R.sub.2, R.sub.4, R.sub.5, R.sub.7, R.sub.8, R.sub.10, and R.sub.11 is a hydrogen atom, each of R.sub.3, R.sub.6, and R.sub.9 is a substituent of Formula; R.sub.12 is selected from a group of substituents represented by Formulae, R.sub.13 is a sulfo group, Ra, Rb, and Rc are substituents independently selected from C.sub.1 to C.sub.6 alkyl groups, and Rd is a hydrogen atom or a C.sub.1 to C.sub.6 alkyl group, and Rx is a substituent represented by General Formula. The porphyrin compound is useful as a cancer therapeutic agent, photosensitizer and fluorescent probe.

There is provided with a porphyrin compound represented by Formula (I) or a salt thereof; ##STR00001## where A is a linking group represented as —X—NHCO— where X is a C.sub.1 to C.sub.6 alkylene group, each of R.sub.1, R.sub.2, R.sub.4, R.sub.5, R.sub.7, R.sub.8, R.sub.10, and R.sub.11 is a hydrogen atom, each of R.sub.3, R.sub.6, and R.sub.9 is a substituent of Formula; R.sub.12 is selected from a group of substituents represented by Formulae, R.sub.13 is a sulfo group, Ra, Rb, and Rc are substituents independently selected from C.sub.1 to C.sub.6 alkyl groups, and Rd is a hydrogen atom or a C.sub.1 to C.sub.6 alkyl group, and Rx is a substituent represented by General Formula. The porphyrin compound is useful as a cancer therapeutic agent, photosensitizer and fluorescent probe.

Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: ##STR00001##
Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.

Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: ##STR00001##
Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.